Xiaoying Yu1,2, Zhiwen Cao2, Wenwen Hou2, Weihua Hu2, Guijun Yan1. 1. Center of Reproductive Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing 210000, China. 2. Center of Reproductive Medicine, Yijishan Hospital of Wannan Medical College, Wuhu 241002, China.
Abstract
BACKGROUND: The effects of letrozole plus human menopausal gonadotropin (HMG) on ovarian stimulation (OS) of intrauterine insemination (IUI) cycles were examined. METHODS: In all, 1,005 IUI cycles were included in this study. Couples underwent natural cycle (NC) IUI (n=150) or IUI after OS with letrozole (n=207) or IUI after OS with letrozole + HMG (n=648). RESULTS: The clinical pregnancy rates were 9.0%, 13.0%, and 17.0%, and the live birth rates were 7.0%, 9.0%, and 14.0% in the NC, letrozole, and letrozole + HMG IUI groups, respectively. The twin pregnancy rate of the letrozole + HMG group (11.0%) was higher than that of the NC (7.0%) and letrozole groups (4.0%). To date, the only triplet pregnancies to occur were in the letrozole + HMG group. On the day of human chorionic gonadotropin (hCG), the number of follicles with an average follicle diameter greater than 18 mm in the letrozole + HMG group (1.21±0.56) and letrozole group (1.14±0.48) was greater than that in the NC group (0.85±0.36). The thickness of the endometrium in the letrozole + HMG group (8.8±2.1 mm) was significantly greater than that in the letrozole group (7.3±1.6 mm). CONCLUSIONS: The letrozole + HMG protocol of OS in IUI can improve follicular development, increase the thickness of endometrium, significantly increase the live birth rate, but not significantly increase the multiple pregnancy rate. 2019 Annals of Translational Medicine. All rights reserved.
BACKGROUND: The effects of letrozole plus human menopausal gonadotropin (HMG) on ovarian stimulation (OS) of intrauterine insemination (IUI) cycles were examined. METHODS: In all, 1,005 IUI cycles were included in this study. Couples underwent natural cycle (NC) IUI (n=150) or IUI after OS with letrozole (n=207) or IUI after OS with letrozole + HMG (n=648). RESULTS: The clinical pregnancy rates were 9.0%, 13.0%, and 17.0%, and the live birth rates were 7.0%, 9.0%, and 14.0% in the NC, letrozole, and letrozole + HMG IUI groups, respectively. The twin pregnancy rate of the letrozole + HMG group (11.0%) was higher than that of the NC (7.0%) and letrozole groups (4.0%). To date, the only triplet pregnancies to occur were in the letrozole + HMG group. On the day of human chorionic gonadotropin (hCG), the number of follicles with an average follicle diameter greater than 18 mm in the letrozole + HMG group (1.21±0.56) and letrozole group (1.14±0.48) was greater than that in the NC group (0.85±0.36). The thickness of the endometrium in the letrozole + HMG group (8.8±2.1 mm) was significantly greater than that in the letrozole group (7.3±1.6 mm). CONCLUSIONS: The letrozole + HMG protocol of OS in IUI can improve follicular development, increase the thickness of endometrium, significantly increase the live birth rate, but not significantly increase the multiple pregnancy rate. 2019 Annals of Translational Medicine. All rights reserved.
Authors: D S Guzick; S A Carson; C Coutifaris; J W Overstreet; P Factor-Litvak; M P Steinkampf; J A Hill; L Mastroianni; J E Buster; S T Nakajima; D L Vogel; R E Canfield Journal: N Engl J Med Date: 1999-01-21 Impact factor: 91.245
Authors: Shuo Huang; Xiaoguo Du; Rui Wang; Rong Li; Haiyan Wang; Li Luo; Sean O'Leary; Jie Qiao; Ben Willem J Mol Journal: Eur J Obstet Gynecol Reprod Biol Date: 2018-08-03 Impact factor: 2.435
Authors: R van Eekelen; N van Geloven; M van Wely; D J McLernon; F Mol; I M Custers; P Steures; S Bhattacharya; B W Mol; F van der Veen; M J Eijkemans Journal: Hum Reprod Date: 2019-01-01 Impact factor: 6.918